Cover VA, a division of the Virginia Department of Medicaid Assistance Services (DMAS), connects eligible Virginians to high-quality, affordable health insurance.
Abbott was recently recognized as an industry leader on The Global Child Forum’s State of Children's Rights and Business Global Benchmark 2021 for implementing policies and practices that address and protect the rights of children.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced the signing of a long-term supply agreement with the United Nations Children’s Fund (UNICEF) to facilitate broad global access for molnupiravir, an investigational
In 1999, with the country ravaged by HIV and its future existence literally in doubt, Botswana embarked on an aggressive plan to curtail the transmission of the virus from mother to child.
The Dr. Martin Luther King, Jr. holiday marks a National Day of Service and an important time of reflection. In 1966 Rev. Dr. Martin Luther King, Jr. spoke at the National Convention of the Medical Committee for Human Rights
Northern Trust is helping to fund a $4.75 million comprehensive home-based asthma program, known as the New York Healthy Homes Collaborative, to improve quality of life for 850 New York City children and adults on Medicaid.
As a middle school math teacher in Woodbridge, Virginia, Dr. Arik King saw firsthand how boys of color trailed their peers in test scores, attendance, and graduation rates—part of an alarming and persistent national trend.
Illumina Inc. (NASDAQ: ILMN) today announced a partnership with Boehringer Ingelheim to develop companion diagnostics (CDx) for several programs in Boehringer Ingelheim's oncology pipeline. The partnership aims to accelerate the development of therapy selection and precision medicines for patients with advanced cancer.
Illumina, Inc. (NASDAQ: ILMN) today announced a multi-year partnership with Agendia N.V., a world leader in precision oncology for breast cancer, to co-develop in vitro diagnostic (IVD) tests for oncology testing. The partnership is intended to advance the use of next-generation sequencing (NGS) for decentralized oncology testing and aligns with Illumina's approach to IVD partnerships in oncology. Agendia joins Illumina's growing portfolio of more than 30 IVD partners developing over 40 sequencing-based solutions for cancer prognosis, therapy selection and other applications.
Illumina, Inc. (NASDAQ: ILMN) and Nashville Biosciences, LLC, a wholly-owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced a multi-year agreement to accelerate medicines development through large-scale genomics and the establishment of a preeminent clinico-genomic resource. Using Illumina's next-generation sequencing (NGS) platforms, scientists and researchers will be able to better identify disease associations and targets for intervention by analyzing data derived from VUMC's extensive, high-quality biobank of approximately 250,000 de-identified human DNA samples and associated longitudinal, structured medical data.
The SCS Kingfisher certification mark is showing up on an increasing number of products around the world. It differentiates companies that are making...
The SCS Kingfisher certification mark is showing up on an increasing number of products around the world. It differentiates companies that are making...
Entergy’s 2024 performance report, “Energy for a better future” presents an overview of our company’s 2024 achievements, future plans and strategies...
The business landscape is reorienting itself and you can almost hear priorities shifting toward change-readiness and the bigger picture. And in this...
Diverse teams build better products — period. At GoDaddy, we make apps and services that our worldwide community of entrepreneurs can relate to. Our...
